Literature DB >> 21364117

Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Souha S Kanj1, Zeina A Kanafani.   

Abstract

The development of antimicrobial resistance among gram-negative pathogens has been progressive and relentless. Pathogens of particular concern include extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Classic agents used to treat these pathogens have become outdated. Of the few new drugs available, many have already become targets for bacterial mechanisms of resistance. This review describes the current approach to infections due to these resistant organisms and elaborates on the available treatment options.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21364117      PMCID: PMC3046948          DOI: 10.4065/mcp.2010.0674

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  101 in total

Review 1.  Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.

Authors:  Johann D D Pitout; Kevin B Laupland
Journal:  Lancet Infect Dis       Date:  2008-03       Impact factor: 25.071

Review 2.  Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.

Authors:  L R Peterson
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

Review 3.  Extended-spectrum beta-lactamases: structure and kinetic mechanism.

Authors:  M G P Page
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

Review 4.  Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.

Authors:  J Garau
Journal:  Clin Microbiol Infect       Date:  2008-01       Impact factor: 8.067

5.  Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Mariana Castanheira; Hélio S Sader; Lalitagauri M Deshpande; Thomas R Fritsche; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

6.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

7.  Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.

Authors:  Jean Chastre; Richard Wunderink; Philippe Prokocimer; Michael Lee; Koné Kaniga; Ian Friedland
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

8.  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

Authors:  Kara B Anthony; Neil O Fishman; Darren R Linkin; Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

9.  Colistin susceptibility testing by Etest and disk diffusion methods.

Authors:  Irene Galani; Flora Kontopidou; Maria Souli; Panagiota-Danai Rekatsina; Evangelos Koratzanis; John Deliolanis; Helen Giamarellou
Journal:  Int J Antimicrob Agents       Date:  2008-03-06       Impact factor: 5.283

10.  Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel.

Authors:  Zmira Samra; Orit Ofir; Yinon Lishtzinsky; Liora Madar-Shapiro; Jihad Bishara
Journal:  Int J Antimicrob Agents       Date:  2007-10-10       Impact factor: 5.283

View more
  80 in total

1.  Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Authors:  Duane Bates; Mike Parkins; Robin Hellweg; Kimberly Gibson; Jennifer M Bugar
Journal:  Can J Hosp Pharm       Date:  2012-05

Review 2.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

Review 3.  Development of novel antibacterial drugs to combat multiple resistant organisms.

Authors:  Matteo Bassetti; Elda Righi
Journal:  Langenbecks Arch Surg       Date:  2015-02-11       Impact factor: 3.445

Review 4.  Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.

Authors:  Seema Patel; Shadab Ahmed; J Satya Eswari
Journal:  World J Microbiol Biotechnol       Date:  2015-06-04       Impact factor: 3.312

5.  Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Jason C Gallagher; Safia Kuriakose; Kevin Haynes; Peter Axelrod
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

6.  Prevalence and drug resistance characteristics of carbapenem-resistant Enterobacteriaceae in Hangzhou, China.

Authors:  Yan Yang; Jian Chen; Di Lin; Xujian Xu; Jun Cheng; Changgui Sun
Journal:  Front Med       Date:  2017-07-08       Impact factor: 4.592

7.  Evaluation of the Accelerate Pheno System for Fast Identification and Antimicrobial Susceptibility Testing from Positive Blood Cultures in Bloodstream Infections Caused by Gram-Negative Pathogens.

Authors:  Matthias Marschal; Johanna Bachmaier; Ingo Autenrieth; Philipp Oberhettinger; Matthias Willmann; Silke Peter
Journal:  J Clin Microbiol       Date:  2017-04-26       Impact factor: 5.948

Review 8.  Plant-derived antimicrobials to fight against multi-drug-resistant human pathogens.

Authors:  Ramesh Subramani; Mathivanan Narayanasamy; Klaus-D Feussner
Journal:  3 Biotech       Date:  2017-06-29       Impact factor: 2.406

9.  Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies.

Authors:  Henri Merdjan; Manickam Rangaraju; Antoine Tarral
Journal:  Clin Drug Investig       Date:  2015-05       Impact factor: 2.859

10.  Antimicrobial activity of ceftaroline-avibactam tested against clinical isolates collected from U.S. Medical Centers in 2010-2011.

Authors:  Helio S Sader; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.